Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.
Analyst Recommendations
This is a breakdown of current ratings for Voyager Therapeutics and Compass Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 2 | 5 | 0 | 2.71 |
| Compass Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Voyager Therapeutics presently has a consensus target price of $17.83, indicating a potential upside of 156.59%. Compass Therapeutics has a consensus target price of $9.00, indicating a potential upside of 669.23%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Voyager Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | 6.28% | 3.31% | 2.33% |
| Compass Therapeutics | N/A | -28.67% | -27.24% |
Valuation & Earnings
This table compares Voyager Therapeutics and Compass Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $250.01 million | 1.52 | $132.33 million | ($0.05) | -138.97 |
| Compass Therapeutics | $850,000.00 | 189.39 | -$42.49 million | ($0.36) | -3.25 |
Voyager Therapeutics has higher revenue and earnings than Compass Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Voyager Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Institutional and Insider Ownership
48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 4.5% of Voyager Therapeutics shares are held by insiders. Comparatively, 30.0% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Voyager Therapeutics beats Compass Therapeutics on 8 of the 14 factors compared between the two stocks.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
